Collen Masimirembwa

Last updated

Collen Masimirembwa
Born1967 (age 56–57)
NationalityZimbabwean
CitizenshipZimbabwe
Occupation(s)President and chief scientific officer of the African Institute of Biomedical Science and Technology
Known for Pharmacogenetics, pharmacology, and drug discovery
AwardsFellow of the African Academy of Sciences, Fellow of the Zimbabwe Academy of Sciences, HUGO Africa Award

Collen Masimirembwa (born 1967) is a biomedical pharmacologist from Zimbabwe. He is a Distinguished Professor of Clinical Pharmacology at the University of Witswatersrand, [1] and serves as the president and chief scientific officer at the African Institute of Biomedical Science and Technology (AiBST). His research in Africa has contributed to the field of pharmacogenetics, particularly in understanding the genetic diversity and drug response of African populations. In 2018, he was awarded the HUGO Africa Award. [2] He is a fellow of the Calestous Juma Leadership Fellowship, [3] African Academy of Sciences (AAS) and the Zimbabwe Academy of Sciences (ZAS).

Contents

He has authored over 100 papers in peer-reviewed journals and book chapters and has guided numerous postgraduate students and postdoctoral fellows. [4]

Early life and education

Masimirembwa was born in 1967 in Zimbabwe [5] and received his BSc (Hons) and DPhil degrees in biochemistry from the University of Zimbabwe in 1993. [6] Fascinated by the then-emerging field of pharmacogenetics, he conducted studies at the Karolinska Institute in Sweden in 1995, [5] where he earned his PhD in Medical Biochemistry and Biophysics. His doctoral research was centered on the molecular mechanisms of drug metabolism and toxicity. [7] [8]

Career and research

After obtaining his PhD, Masimirembwa returned to the University of Zimbabwe and served as a senior lecturer and head of the Department of Biochemistry from 1992 to 1997. [6] He later joined AstraZeneca R&D in Sweden as a principal scientist and project leader, focusing on drug discovery and development in various areas such as cardiovascular, gastrointestinal, and infectious diseases. He played a key role in establishing the AstraZeneca Africa Pharmacogenetics Research Network, which aimed to study the genetic diversity and drug response of African populations. [7] [6]

Later in 2008, Masimirembwa founded and assumed the position of president and chief scientific officer at the African Institute of Biomedical Science and Technology (AiBST), a non-profit research institute in Zimbabwe that focuses on biomedical science and technology, with an emphasis on pharmacogenetics and clinical pharmacology. [9]

At the institute, he manages collaborations with various academic, industry, and government partners. He also leads the African Pharmacogenomics Consortium (APC), a network that aims to advance pharmacogenomics research and applications in Africa. [6] He is also a distinguished professor of health sciences research at the University of the Witwatersrand (South Africa). [7] [10]

Masimirembwa is a fellow of the Zimbabwe Academy of Sciences (ZAS) [5] and the African Academy of Sciences (AAS) among many other honors. In November 2021, Masimirembwa was selected as a Calestous Juma Science Leadership Fellow by the Bill and Melinda Gates Foundation, to develop a research and innovation ecosystem, train scientists, and create centres of excellence in genomic medicine research to enhance Africa’s sustainable development in genomic and pharmaceutical capabilities. [11]

Selected publications

Awards

Collen Masimirembwa was named a Fellow of the Zimbabwe Academy of Sciences in 2017 and the African Academy of Sciences in 2018. In 2018, he was awarded the HUGO Africa Award. [12] The Grand Challenges Africa Award was presented to him in 2016. He was the recipient of the EDCTP Senior Fellowship Award in 2014 [13] and the Wellcome Trust Senior Fellowship Award in 2012. AstraZeneca R&D acknowledged his work with the Global Scientific Award in 2006 and the Global Innovation Award in 2005. [7] [11] Additionally, he received the Calestous Juma Leadership Fellowship in 2021 [14] and the PMCW 2025 Pioneer Award. [15]

Related Research Articles

<span class="mw-page-title-main">Pharmacology</span> Science of drugs and medications and their effects

Pharmacology is the science of drugs and medications, including a substance's origin, composition, pharmacokinetics, pharmacodynamics, therapeutic use, and toxicology. More specifically, it is the study of the interactions that occur between a living organism and chemicals that affect normal or abnormal biochemical function. If substances have medicinal properties, they are considered pharmaceuticals.

<span class="mw-page-title-main">Omeprazole</span> Medication to treat gastroesophageal reflux disease and other conditions

Omeprazole, sold under the brand names Prilosec and Losec, among others, is a medication used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger–Ellison syndrome. It is also used to prevent upper gastrointestinal bleeding in people who are at high risk. Omeprazole is a proton-pump inhibitor (PPI) and its effectiveness is similar to that of other PPIs. It can be taken by mouth or by injection into a vein. It is also available in the fixed-dose combination medication omeprazole/sodium bicarbonate as Zegerid and as Konvomep.

<span class="mw-page-title-main">Pharmacogenomics</span> Study of the role of the genome in drug response

Pharmacogenomics, often abbreviated "PGx," is the study of the role of the genome in drug response. Its name reflects its combining of pharmacology and genomics. Pharmacogenomics analyzes how the genetic makeup of a patient affects their response to drugs. It deals with the influence of acquired and inherited genetic variation on drug response, by correlating DNA mutations with pharmacokinetic, pharmacodynamic, and/or immunogenic endpoints.

<span class="mw-page-title-main">CYP2D6</span> Human liver enzyme

Cytochrome P450 2D6 (CYP2D6) is an enzyme that in humans is encoded by the CYP2D6 gene. CYP2D6 is primarily expressed in the liver. It is also highly expressed in areas of the central nervous system, including the substantia nigra.

<span class="mw-page-title-main">Calestous Juma</span> Kenyan academic

Calestous Juma was a Kenyan scientist and academic, specializing in sustainable development. He was named one of the most influential 100 Africans in 2012, 2013 and 2014 by the New African magazine. He was Professor of the Practice of International Development and Faculty Chair of the Innovation for Economic Development Executive Program at Harvard Kennedy School. Juma was Director of the School's Science, Technology and Globalization Project at Harvard Kennedy School as well as the Agricultural Innovation in Africa Project funded by the Bill and Melinda Gates Foundation.

<span class="mw-page-title-main">CYP2C19</span> Mammalian protein found in humans

Cytochrome P450 2C19 is an enzyme protein. It is a member of the CYP2C subfamily of the cytochrome P450 mixed-function oxidase system. This subfamily includes enzymes that catalyze metabolism of xenobiotics, including some proton pump inhibitors and antiepileptic drugs. In humans, it is the CYP2C19 gene that encodes the CYP2C19 protein. CYP2C19 is a liver enzyme that acts on at least 10% of drugs in current clinical use, most notably the antiplatelet treatment clopidogrel (Plavix), drugs that treat pain associated with ulcers, such as omeprazole, antiseizure drugs such as mephenytoin, the antimalarial proguanil, and the anxiolytic diazepam.

The International Union of Basic and Clinical Pharmacology (IUPHAR) is a voluntary, non-profit association representing the interests of scientists in pharmacology-related fields to facilitate Better Medicines through Global Education and Research around the world.

<span class="mw-page-title-main">Russ Altman</span> American biomedical scientist and academic

Russ Biagio Altman is an American professor of bioengineering, genetics, medicine, and biomedical data science and past chairman of the bioengineering department at Stanford University.

David Ofori-Adjei is a Ghanaian physician, medical researcher, academic and medical journal editor. His main areas of research are clinical pharmacology, pharmacogenetics, infectious diseases such as malaria, schistosomiasis, Buruli ulcer, and HIV/AIDS and public sector pharmaceutical management. He is currently the Editor-in-Chief of the Ghana Medical Journal.

<span class="mw-page-title-main">Samsung Biologics</span> South Korean biotechnology company

Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.

Professor Sir Munir Pirmohamed is a British clinical pharmacologist and geneticist. Since 2007 he has been the NHS Chair of Pharmacogenetics at the University of Liverpool.

<span class="mw-page-title-main">Chinedum Babalola</span> Nigerian pharmacist and academic

Chinedum Peace BabalolaFAS, FAAS is a Nigerian Professor of Pharmaceutical chemistry and Pharmacokinetics. She teaches pharmacy at the University of Ibadan, FAS, and FAAS while also being the first Vice Chancellor of Chrisland University, Nigeria.

Sandhya Srikant Visweswariah is a scientist and academic at the Indian Institute of Science, Bangalore, India. She was the Chairperson of the Department of Developmental Biology and Genetics and the Co-chair of the Department of Bioengineering, Indian Institute of Science. She additionally holds the position of Adjunct Professor, Faculty of Medicine and Dentistry, University of Bergen, Norway. Her research involves the investigation of the mechanism of signal transduction via cyclic nucleotides, phosphodiesterases and novel cyclases in bacteria. Most recently, she was awarded a Bill and Melinda Gates Grand Challenges Explorations Grant for her proposal entitled "A Small Animal Model of ETEC-Mediated Diarrhea".

<span class="mw-page-title-main">Thomas Kariuki</span> Biologist (b. 1962)

Thomas M. Kariuki is a Kenyan biologist who is Chief Executive Officer of the Science for Africa Foundation. Kariuki previously served as the Director of Programmes for the Alliance for Accelerating Excellence in Science in Africa (AESA). He was the Director of the Institute of Primate Research/National Museums of Kenya, for seven years. Kariuki’s research interests have spanned the immunology of neglected infectious diseases and he has been involved in global efforts to develop vaccines, drugs and diagnostics for poverty-related diseases. He has published on vaccines and diagnostics development for schistosomiasis (Bilharzia), malaria and co-infections and on policy issues related to biomedical research and funding. He is a Fellow of the African Academy of Sciences (AAS), Senior Fellowship of the European Foundations Initiative for Neglected Tropical Diseases, Presidential honour of the Order of Grand Warrior of Kenya (OGW) for scientific leadership and public service, Honorary Professor of Research of the Liverpool School of Tropical Medicine, LSTM.

Sussan Nourshargh is a British immunologist, pharmacologist, and professor of microvascular pharmacology and immunopharmacology. She founded the Centre for Microvascular research at Queen Mary University.

Iruka Okeke is a Nigerian pharmaceutical microbiologist currently holding the position of professor at the College of Medicine,University of Ibadan in Nigeria. Iruka's career is the study neglected enteric bacteria such as E. coli, known for their potential to cause fatal bloodstream and diarrheal infections. She advocates for the utilization of Genomics approaches to enhance surveillance and gain a better understanding of pathogen virulence. Iruka's research interests extend to combating antimicrobial resistance and investigating bacterial pathogenesis, epidemiology, and antimicrobial resistance of enteric bacteria. Iruka's contributions to the field have earned her recognition as a fellow of esteemed institutions such as the Nigerian Academy of Sciences, and African Academy of Sciences.[1]

<span class="mw-page-title-main">Julie A. Johnson</span> American clinical pharmacist

Julie Ann Johnson is an American clinical pharmacist and translational scientist. She currently serves as associate dean for clinical and translational research and holds the Dr. Samuel T. and Lois Felts Mercer Professorship of Medicine and Pharmacology at Ohio State University College of Medicine. She is also associate vice president for research at Ohio State.

<span class="mw-page-title-main">Ruth March</span> British genomic scientist

Ruth Eleanor March is a British genomic scientist who is senior vice president of precision medicine at AstraZeneca. She specialises in precision medicine and oncology. During the COVID-19 pandemic, March developed a diagnostic test for COVID-19.

<span class="mw-page-title-main">Matthias Schwab (pharmacologist)</span> German pharmacologist

Matthias Schwab is a German doctor and university lecturer. He is director of the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology located on the campus of the Robert-Bosch-Hospital in Stuttgart, an institution of the Robert Bosch Stiftung, and holder of the Chair of Clinical Pharmacology at the University of Tübingen as well as Medical Director of the Department of Clinical Pharmacology at the University Hospital Tübingen.


Moses Obimbo Madadi, is a Kenyan clinician - scientist, researcher, and educator. He is Professor and Chairman of the Department of Human Anatomy and Medical Physiology at the University of Nairobi; and serves as an obstetrician and gynaecologist at The Kenyatta National Hospital. Obimbo is also the Honorary Secretary of The Kenya Obstetrical and Gynaecological Society.

References

  1. ↑ "ISP Stories - Uppsala University". www.uu.se. 13 May 2024. Retrieved 7 August 2024.
  2. ↑ International, HUGO. "HUGO African Prize". HUGO International. Retrieved 7 August 2024.
  3. ↑ "Collen Masimirembwa". gcgh.grandchallenges.org. Retrieved 7 August 2024.
  4. ↑ "My Bibliography - NCBI". www.ncbi.nlm.nih.gov. Retrieved 7 August 2024.
  5. 1 2 3 "Collen Masimirembwa". urban-press. Retrieved 30 December 2023.
  6. 1 2 3 4 "Dr. Collen Masimirembwa, President and Founder of The African Institute of Biomedical Science and Technology, Harare, Zimbabwe" (PDF). Retrieved 30 December 2023.
  7. 1 2 3 4 "Collen MASIMIREMBWA". ICGEB. 16 April 2023. Retrieved 30 December 2023.
  8. ↑ "International Science Programme (ISP)". Uppsala University, Sweden. 14 September 2023. Retrieved 30 December 2023.
  9. ↑ Olagunju, Abdulrahman (12 October 2023). "Increasing breast cancer drug dose would improve outcomes for black patients".
  10. ↑ "Professor Collen Masimirembwa". EDCTP. 24 July 2020. Retrieved 30 December 2023.
  11. 1 2 "Collen Masimirembwa". Global Grand Challenges. 15 October 2021. Retrieved 30 December 2023.
  12. ↑ International, HUGO. "HUGO African Prize". HUGO International. Retrieved 6 August 2024.
  13. ↑ EDCTP2 portfolio: fellowship programme. Retrieved 30 August 2024
  14. ↑ "Collen Masimirembwa". gcgh.grandchallenges.org. Retrieved 6 August 2024.
  15. ↑ "Awards - PMWC Silicon Valley". PMWC Precision Medicine World Conference. Retrieved 6 August 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.